Steve Elias (Englewood, USA) talks to Venous News about the pivotal trial of high-intensity focused ultrasound (HIFU) using the Sonovein (Theraclion) device during the 2026 American Venous Forum (AVF) in Denver, USA (28 February–4 March). Elias had just presented the complete results showing its safety and efficacy in treating primary insufficiency of the great saphenous vein (GSV), with an occlusion rate of 96.8% and reflux abolition rate of 98.6%.
